March/April - West Virginia State Medical Association

Scientific Article |
Figure 2.
A 66 year old female on alendronate for 7 years noted bilateral thigh pain for several
weeks. When turning from a standing position, she experienced severe thigh pain and
was caught by a friend. A transverse fracture was noted at a thickened cortical site (a).
Nuclear imaging revealed a contralateral stress reaction (b).
Figure 3.
A 68 year-old white female who received
estrogen and bisphosphonates for 5.5
years experienced right thigh pain for 2
weeks causing her to fall which resulted
in a subtrochanteric fracture.
orthopedists William G. Sale, MD
and Tony C. Majestro, MD for their
review of cases and radiographic
images; and the late Paul D.
Saville, MD for his comments.
References
1. Chavassieux P, Seeman E, Delmas PD.
Insights into the material and structural
basis of bone fragility from diseases
associated with fracture: How determinants
of the biomechanical properties of bone are
compromised by disease. Endocrine
Reviews. 2007;28:151-164.
2. NIH Consensus Development Panel on
Osteoporosis, Diagnosis, and Therapy.
Osteoporosis diagnosis, and therapy. JAMA
2001;285:785-795.
3. Greenspan S, Parker RA, Ferguson L,
Rosen HN, Maitland-Ramsey L, Karpf DB.
Early changes in biochemical markers of
bone turnover predict the long-term
response to alendrodronate therapy in
representative elderly women. J Bone Miner
Res 1998;13:1431- 1438.
4. Cummings SR, Karpf DB, Harris F, et al.
Improved spine bone mineral density and
reduction in risk of vertebral fractures during
treatment with antiresorptive drugs. Am J
Med. 2002;112;281-289.
5. Wells GA, Craney A, Peterson J, et al.
Alendronate for the primary and secondary
prevention of osteoporotic fractures in
postmenopausal women. Cochrane
Database of Systematic Reviews. 2008,
Issue 1. Art No.:CD001155.
DOI:10.1002/14651858. CD001155.pub2.
6. Bone HG, Hosking D, Devogelaer J-P, et al.
Ten years’ experience with alendronate for
osteoporosis. New Engl J Med
2004;350:1189-1199.
7. Tonino R, Meunier PJ, Emkey R, et al.
Skeletal benefits of alendronate: 7-Year
treatment of postmenopausal osteoporotic
women. J Clin Endocrinol Metab
2000;85:3109-3115.
8. Black DM, Schwartz AV,Ensrud KE, et al.
Effects of continuing or stopping
alendronate after 5 years of treatment.
JAMA 2006;296:2927-2938.
9. Ott SM. Fractures after long-term
alendronate therapy. J Clin Endocrinol
Metab. 2001;86: 1835.
10. Hirano T, Turner CH, Forwood MR,
Johnston CC, Burr DB. Does suppression
of bone turnover impair mechanical
properties by allowing microdamage
accumulation Bone. 2000;21:13-20.
11. Odvina CV, Zerwekh JE, Sudhaker Rao D,
Maalouf N, Gottshalk FA, Pak CYC.
Severely suppressed bone turnover: A
potential complication of alendronate
therapy. J Clin Endo- crinol Metab.
2005;90:1294-1301.
12. Goh SK, Yang KY, Koh JSB, et al.
Subtrochanteric insufficiency fractures in
patients on alendronate therapy: A caution.
J Bone Joint Surg Br. 2007;89:349-353.
13. Cheung RKH, Leung KK, Lee KC, Chow
TC. Sequential non-traumatic femoral neck
fractures in a patient on long-term
alendronate. Hong Kong Med J.
2007;13:485-489.
12 West Virginia Medical Journal